MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00296-023-05310-9

Медицинская библиотека · Rheumatology international · 2023

Systemic sclerosis and COVID-19 vaccine safety: short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey.

Naveen R, Thakare Darpan R, Kuwana Masataka, Pauling John D, Day Jessica, Joshi Mrudula, Parodis Ioannis, Sen Parikshit, Jagtap Kshitij, Nikiphorou Elena, Saha Sreoshy, Agarwal Vishwesh, Chatterjee Tulika, Lilleker James B, Kardes Sinan, Milchert Marcin, Gheita Tamer, Salim Babur, Velikova Tsvetelina, Gracia-Ramos Abraham Edgar, Tan Ai Lyn, Nune Arvind, Cavagna Lorenzo, Saavedra Miguel A, Shinjo Samuel Katsuyuki, Ziade Nelly, Knitza Johannes, Distler Oliver, Chinoy Hector, COVAD Study Group, Aggarwal Rohit, Gupta Latika, Agarwal Vikas, Makol Ashima

СтатьяПеревод в очереди

Аннотация

The safety profile of COVID-19 vaccines is understudied in patients with systemic sclerosis (SSc). We compared short-term adverse events (AEs) 7 days following vaccination in patients with SSc vs other rheumatic (AIRDs), non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HCs). The COVID-19 Vaccination in autoimmune diseases (COVAD) self-reporting e-survey was circulated by a group of > 110 collaborators in 94 countries from March to December 2021. AEs were analyzed between different groups using regression models. Of 10,679 complete respondents [73.8% females, mean age 43 years, 53% Caucasians], 478 had SSc. 83% had completed two vaccine doses, Pfizer-BioNTech (BNT162b2) (51%) was the most common. Minor and major AEs were reported by 81.2% and 3.3% SSc patients, respectively, and did not differ significantly with disease activity or different vaccine types, though with minor symptom differences. Frequencies of AEs were not affected by background immunosuppression, though SSc patients receiving hydroxychloroquine experienced fatigue less commonly (OR 0.4; 95% CI 0.2-0.8). Frequency of AEs and hospitalisations were similar to other AIRDs, nrAIDs, and HC except a higher risk of chills (OR 1.3; 95% CI 1.0-1.7) and fatigue (OR 1.3; 95% CI 1.0-1.6) compared to other AIRDs. COVID-19 vaccines were largely safe and well tolerated in SSc patients in the short term. Background immunosuppression and disease activity did not influence the vaccination-related short-term AEs.

Для цитирования: Naveen R, Thakare Darpan R, Kuwana Masataka, Pauling John D, Day Jessica, Joshi Mrudula, Parodis Ioannis, Sen Parikshit, Jagtap Kshitij, Nikiphorou Elena, Saha Sreoshy, Agarwal Vishwesh, Chatterjee Tulika, Lilleker James B, Kardes Sinan, Milchert Marcin, Gheita Tamer, Salim Babur, Velikova Tsvetelina, Gracia-Ramos Abraham Edgar, Tan Ai Lyn, Nune Arvind, Cavagna Lorenzo, Saavedra Miguel A, Shinjo Samuel Katsuyuki, Ziade Nelly, Knitza Johannes, Distler Oliver, Chinoy Hector, COVAD Study Group, Aggarwal Rohit, Gupta Latika, Agarwal Vikas, Makol Ashima. Systemic sclerosis and COVID-19 vaccine safety: short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey.. Rheumatology international. 2023. DOI: 10.1007/s00296-023-05310-9.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.